Clinical Trials Logo

Clinical Trial Summary

Prospective observational multicenter study in European ICUs. All patients admitted to the ICU for probable or confirmed Acute encephalitis (2013 IDSA - Infectious Disease Society of America criteria) will be included. Factors associated with a poor prognosis will be identified by multivariate analysis using a logistic regression.


Clinical Trial Description

Primary objective : evaluate the correlation between mRs score and the baseline characteristics Functional outcomes will be evaluated using the modified Rankin score (mRS) score, which is one of the most frequently used scores in acute neurological diseases [18]. A poor outcome will be defined by a mRS score > 2 (functional dependence or death). The investigator usually evaluates this score if the patient is still in the hospital 90 days after admission. Patients discharged from hospital within 90 days following ICU admission without major disability (mRS 0, 1 or 2) are considered to have a good outcome. Patients discharged within 90 days with a disability will be classified for the study according to the latest available data. Patients will not be contacted directly by the investigator for the study purposes. Secondary objectives : To identify additional prognosis factors : the clinical, radiological, biological and neurophysiological factors associated with poor outcome for patients admitted to the ICU with AE - Day 28 mortality, in-ICU mortality, in-hospital mortality - Major systemic complications (septic shock, hyponatremia, nosocomial pneumonia, catheter-related BSI, overt gastroenteral bleeding, pulmonary embolism) - Major intracranial complications during ICU stay - Status epilepticus - Brain death - Empyema/cerebral abscess - Cerebral ischemia - Intracranial bleeding - ICP monitoring - Neurosurgery The cause of death will be categorized into 2 categories: - Systemic causes (cardiovascular failure, MOF) - Neurological cause (Diffuse neurologic injury or withdrawal of care) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03144570
Study type Observational [Patient Registry]
Source ICUREsearch
Contact
Status Completed
Phase
Start date June 1, 2017
Completion date December 31, 2020

See also
  Status Clinical Trial Phase
Completed NCT02538094 - tDCS and Cognition in Adults With Multiple Sclerosis or Encephalitis N/A
Completed NCT00381433 - Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid Phase 1
Completed NCT00031486 - Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir Phase 3
Completed NCT00069303 - Natural History of West Nile Virus Infection N/A
Completed NCT02906631 - Epidemiology and Prognosis of Encephalitis in Intensive Care
Completed NCT02367664 - A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants Phase 3
Completed NCT00314132 - Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis. Phase 3
Terminated NCT00927953 - Treatment of West Nile Virus With MGAWN1 Phase 2
Recruiting NCT05393492 - Regulating Emotions and Behaviors After Brain Injury N/A
Terminated NCT04361344 - Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection N/A
Recruiting NCT04460599 - Neurological Features During COVID19
Recruiting NCT04372615 - The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis Phase 2
Completed NCT02714959 - IL-2 in Refractory Autoimmune Encephalitis Phase 1/Phase 2
Completed NCT01092507 - A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers Phase 3
Completed NCT01041573 - Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population Phase 3
Not yet recruiting NCT04722328 - Establishment of Prevention and Control System of Central Nervous System Infection
Recruiting NCT06067750 - Comparison of Narcotrend and Cerebral Function Analysing Monitor in Intensive Care to Monitor Seizures and Deep Sedation
Not yet recruiting NCT06368648 - CoMind Early Feasibility Study
Completed NCT02526550 - Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX Phase 4
Completed NCT01694524 - Nervous System Infections Among Patients With Febrile Seizure N/A